Contrasting Theravance Biopharma (TBPH) & Its Peers

Theravance Biopharma (NASDAQ:TBPH) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Theravance Biopharma to related companies based on the strength of its institutional ownership, risk, earnings, valuation, profitability, dividends and analyst recommendations.

Volatility and Risk

Theravance Biopharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Theravance Biopharma’s peers have a beta of -4.10, meaning that their average stock price is 510% less volatile than the S&P 500.

Profitability

This table compares Theravance Biopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Theravance Biopharma Competitors	-2,381.29%	-218.58%	-15.77%

Institutional and Insider Ownership

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.6% of Theravance Biopharma shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Theravance Biopharma and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Theravance Biopharma	$104.31 million	$105.89 million	16.86
Theravance Biopharma Competitors	$5.33 billion	$3.21 billion	549.58

Theravance Biopharma’s peers have higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for Theravance Biopharma and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	7	0	0	2.00
Theravance Biopharma Competitors	7782	13872	25761	1035	2.41

Theravance Biopharma presently has a consensus target price of $19.00, indicating a potential upside of 11.57%. As a group, “Pharmaceuticals” companies have a potential upside of 28.52%. Given Theravance Biopharma’s peers stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma has less favorable growth aspects than its peers.

Summary

Theravance Biopharma peers beat Theravance Biopharma on 8 of the 13 factors compared.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.